On February 18, 2015 The Wall Street Journal (WSJ) published a response to its recent editorial on bisphenol A (BPA, CAS 80-05-7) that calls for reallocation of resources for BPA studies to other, more productive research projects (FPF reported). In the letter to editors of WSJ, Andrea Gore, professor at the University of Texas at Austin and the Editor-in-Chief for the journal Endocrinology, emphasizes that nearly 100 peer-reviewed epidemiological studies are available that link BPA with human health problems. BPA is a known endocrine disrupting chemical (EDC), Gore notes. EDCs have effects at extremely low doses, usually below those used in standard toxicology testing. Yet, they can trigger significant biological changes. However, the U.S. Food and Drug Administration (FDA) continues to assess BPA using standards unsuitable for EDCs. Further, the design of the Teeguarden et al. study (FPF reported) mentioned in the WSJ opinion was not suitable to assess immediate BPA absorption, Gore emphasizes. Regardless of the exposure route, the U.S. Centers for Disease Control and Prevention (CDC) estimate that 96% of Americans have some level of BPA in their body. In order to effectively evaluate BPA hazards posed to humans, regulators need to take into account the low-dose effects of BPA, Gore concludes.
Andrea Gore (February 18, 2015). “Endocrine disruption and BPA use.” The Wall Street Journal